<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03974100</url>
  </required_header>
  <id_info>
    <org_study_id>CGP24112301</org_study_id>
    <nct_id>NCT03974100</nct_id>
    <nct_alias>NCT03991338</nct_alias>
  </id_info>
  <brief_title>Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis</brief_title>
  <official_title>A Randomized, Double-blind, Multicenter Integrated Phase I/III Study in Postmenopausal Women With Osteoporosis to Compare the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety and Immunogenicity of GP2411 (Proposed Biosimilar Denosumab) and Prolia® (EU-authorized)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hexal AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, parallel arm, double-blind study with a total duration up&#xD;
      to 82 weeks. Approximately 522 postmenopausal patients with osteoporosis will be randomized&#xD;
      at the beginning of Treatment Period 1 (Baseline to Week 52) to receive 2 doses of either&#xD;
      GP2411 or EU-authorized Prolia.&#xD;
&#xD;
      At the beginning of Treatment Period 2 (Week 52 to Week 78) patients in Treatment Period 1&#xD;
      Prolia group will be re-randomized 1:1 to either continue with a third dose of EU- authorized&#xD;
      Prolia, or transition to GP2411. All patients in the GP2411 group will continue the treatment&#xD;
      with a third dose of GP2411.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2, 2019</start_date>
  <completion_date type="Anticipated">July 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 25, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline (%CfB) in lumbar spine Bone Mineral Density</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Treatment Period 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the effect versus time curve (AUEC) after first dose, percent change from baseline in serum Collagen C-telopeptide (CTX)</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Treatment Period 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum PK parameter AUCinf after first dose</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Treatment Period 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum PK parameter Cmax after first dose</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Treatment Period 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Bone Mineral Density at femoral neck and total hip by DXA</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Treatment Period 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTX serum concentration</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Treatment Period 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of adverse events and serious adverse events</measure>
    <time_frame>Screening, Week 52</time_frame>
    <description>Treatment Period 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibodies (ADAs) serum concentration</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Treatment Period 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline of Bone Mineral density at lumbar spine, femoral neck and total hip by DXA</measure>
    <time_frame>Week 52, Week 78</time_frame>
    <description>Treatment Period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTX serum concentration</measure>
    <time_frame>Week 52, week 78</time_frame>
    <description>Treatment Period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and serious adverse events</measure>
    <time_frame>Week 52, Week 78</time_frame>
    <description>Treatment Period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procollagen 1 N-terminal propeptide (P1NP) serum concentration</measure>
    <time_frame>Week 52, Week 78</time_frame>
    <description>Treatment Period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P1NP serum concentration</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Treatment Period 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibodies (ADAs) serum concentration</measure>
    <time_frame>Week 52, Week 78</time_frame>
    <description>Treatment Period 2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">527</enrollment>
  <condition>Postmenopausal Women With Osteoporosis</condition>
  <arm_group>
    <arm_group_label>GP2411</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg /mL subcutaneous injection every 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU authorized Prolia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 mg /mL subcutaneous injection every 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GP2411</intervention_name>
    <description>60 mg /mL subcutaneous injection every 6 months</description>
    <arm_group_label>GP2411</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EU authorized Prolia</intervention_name>
    <description>60 mg /mL subcutaneous injection every 6 months</description>
    <arm_group_label>EU authorized Prolia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal women, diagnosed with osteoporosis&#xD;
&#xD;
          -  Aged ≥ 55 and ≤ 80 years at screening&#xD;
&#xD;
          -  Body weight ≥ 50 kg and ≤ 90 kg at screening&#xD;
&#xD;
          -  Absolute bone mineral density consistent with T-score ≤ -2.5 and ≥ -4.0 at the lumbar&#xD;
             spine as measured by DXA&#xD;
&#xD;
          -  At least two vertebrae in the L1-L4 region and at least one hip joint are evaluable by&#xD;
             DXA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous exposure to denosumab (Prolia, Xgeva, or biosimilar denosumab)&#xD;
&#xD;
          -  History and/or presence of one severe or more than two moderate vertebral fractures or&#xD;
             hip fracture&#xD;
&#xD;
          -  History and/or presence of bone metastases, bone disease or metabolic disease&#xD;
&#xD;
          -  Ongoing use of any osteoporosis treatment or use of prohibited treatment&#xD;
&#xD;
          -  Other bone active drugs&#xD;
&#xD;
          -  History and/or current hypoparathyroidism or hyperparathyroidism, hypocalcemia or&#xD;
             hypercalcemia&#xD;
&#xD;
        Other Inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Postmenopausal women, diagnosed with osteoporosis</gender_description>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4001</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1505</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1680</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Ostrava</city>
        <state>Czech Republic</state>
        <zip>772 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <state>CZE</state>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Plzen</city>
        <zip>30460</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Praha 11</city>
        <zip>148 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 50</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Fujimi</city>
        <state>Saitama</state>
        <zip>354-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Chuoh-ku</city>
        <state>Tokyo</state>
        <zip>104-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Hachioji-city</city>
        <state>Tokyo</state>
        <zip>192-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Kiyose-city</city>
        <state>Tokyo</state>
        <zip>204-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Shinagawa</city>
        <state>Tokyo</state>
        <zip>140-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-461</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85 168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>90 242</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Nadarzyn</city>
        <zip>05-830</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>00-874</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02 118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02 691</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruna</state>
        <zip>15705</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

